Alembic Pharmaceuticals announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The company reported revenue of INR 19.10 Bn for the quarter, a 16% YoY increase. EBIDTA stood at INR 3.24 Bn, with a margin of approximately 17%. The company’s India Branded Business grew by 5%, while US Generics saw a 21% increase.
Financial Performance
Alembic Pharmaceuticals announced its financial performance for the quarter and half-year ended September 30, 2025. Key highlights include:
- Revenue for Q2 2026 reached INR 19.10 Bn, reflecting a 16% YoY growth.
- EBIDTA for Q2 2026 was reported at INR 3.24 Bn, with an EBIDTA margin of approximately 17%, marking a 26% YoY increase.
- Net Profit for Q2 2026 amounted to INR 1.85 Bn, with a net profit margin of 10%, showing a 20% YoY growth.
- The company’s R&D expenditure accounted for 10% of revenue, representing a 41% YoY increase.
Business Segment Performance
India Branded Business
The India Branded Business achieved a 5% YoY growth, generating quarterly revenues of INR 6.39 billion. Alembic is ranked 20th in the Indian Pharmaceutical Market (IPM).
US Generics
The US Generics business reported a 21% YoY increase, driven by key product launches and market share gains in select therapies. Seven products were launched in H1 FY26, bringing the total number of commercialized products in the US to 170.
Ex-US Generics
The Ex-US Generics segment experienced a 31% YoY growth. The company’s focus remains on expanding offerings and enhancing market coverage in these regions.
API Business
The API business recorded a 15% YoY increase, driven by volume growth.
Animal Health Business
The Animal Health division recorded 17% growth. A well-established portfolio of strong brands continues to drive growth.
Key Initiatives
- Continued investment in building product pipelines.
- Rising ANDA filings and approvals.
Source: BSE